About this trial
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.
Eligibility criteria
Qualifiers
Diagnosis: AML (exlusion of secondary disease)
Disease status at time of HSCT: complete remission
Karnofsky performance status: ≥80%
Source of HSC: PBSC
Disqualifiers
Prior transplant
Uncontrolled Malignancy
Trial design
Treatments tested in this trial
- blood draw